Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharm

GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rig

Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported succe

Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy o

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus t

Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOps

Development targeted for the treatment of neovascular age-related macular degeneration (nAMD), diabe

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Glaukos said on Wednesday patients treated with its late-stage eye disease therapy maintained improv

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 2.33% on an annualized bas

Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad p

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 1.4% on an annualized basi

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Squarepoint Ops LLC reduced its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 86.9% duri

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 3.9% on an annualized basi

Corient Private Wealth LP acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefi

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Algert Global LLC lessened its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 43.0% in th

Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized bas

Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quart

Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a b

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline s

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Small-cap stocks are surging, but how you own them matters more than most investors realize.

UBS analyst Patrick Wood maintains Glaukos (NYSE:GKOS) with a Neutral and raises the price target

HC Wainwright & Co. analyst Yi Chen maintains Glaukos (NYSE:GKOS) with a Buy and raises the p

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta

Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE:GKOS) with a Overweight and raises the

Stifel analyst Tom Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target f

Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:GKOS) with a Buy and raises th

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:GKOS) with a Overweight and raises th

Needham analyst David Saxon maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

Glaukos (NYSE:GKOS) raises FY2026 sales outlook from $620.000 million-$635.000 million to $680.000 m

Glaukos (NYSE:GKOS) reported quarterly losses of $(0.14) per share which beat the analyst consensus

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Stifel analyst Tom Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target f

Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:GKOS) with a Buy and raises th

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta

HC Wainwright & Co. analyst Yi Chen initiates coverage on Glaukos (NYSE:GKOS) with a Buy rati

Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE:GKOS) with a Overweight and maintains

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused